FHTX Foghorn Therapeutics Inc.companySEC Filings & Insider Trading Activity 2026
Latest Foghorn Therapeutics Inc. (FHTX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 11, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 21, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Foghorn Therapeutics Inc. (FHTX) (SEC CIK 1822462), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Full-year 2025 financial results announced March 11, 2026 — details in Exhibit 99.1 press release
- • FHTX is a clinical-stage biotech; cash runway and R&D spend are key metrics to watch in the release
Item 7.01: Regulation FD Disclosure
- • Foghorn Therapeutics (FHTX) releasing updated investor presentation dated March 2026 for use in investor meetings
- • Reg FD disclosure ensures all investors receive simultaneous access to material information shared in these meetings
Item 8.01: Other Events
- • Press release filed Feb 23, 2026 announcing management changes — details in Exhibit 99.1
- • Leadership transitions at clinical-stage biotechs can signal strategic pivots or pipeline reprioritization
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Ryan D. Maynard appointed CFO effective Feb 23, 2026; replaces interim CFO Jeff Sacher
- • Base salary $510,000 with 40% target annual bonus (~$204,000) and $90,000 signing bonus
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Foghorn Therapeutics Inc. (FHTX) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 21, 2026 | — | — | — |
8-K | Mar 11, 2026 | — | Analysis | — |
10-K | Mar 11, 2026 | Dec 31, 2025 | — | |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 4, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-K | Mar 6, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 4, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 6, 2024 | Mar 31, 2024 | — | |
10-K | Mar 7, 2024 | Dec 31, 2023 | — | |
10-Q | Aug 4, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Mar 9, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Mar 10, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 10, 2021 | Jun 30, 2021 | — | |
10-Q | May 11, 2021 | Mar 31, 2021 | — | |
10-K | Mar 18, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest FHTX SEC filings in 2026?
Foghorn Therapeutics Inc. (FHTX) has filed a 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 21, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did FHTX file its most recent 10-K annual report?
Foghorn Therapeutics Inc. (FHTX) filed its most recent 10-K annual report on March 11, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view FHTX 10-Q quarterly reports?
Foghorn Therapeutics Inc. (FHTX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every FHTX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has FHTX filed recently?
Foghorn Therapeutics Inc. (FHTX)'s most recent 8-K was filed on April 21, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find FHTX insider trading activity (Form 4)?
SignalX aggregates every FHTX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does FHTX file with the SEC?
Foghorn Therapeutics Inc. (FHTX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new FHTX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Foghorn Therapeutics Inc. (FHTX).
What is FHTX's SEC CIK number?
Foghorn Therapeutics Inc. (FHTX)'s SEC CIK (Central Index Key) number is 1822462. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1822462 to look up all FHTX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find FHTX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Foghorn Therapeutics Inc. (FHTX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Foghorn Therapeutics Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 26+ filings.